More exploration of combining other pharmacological treatment strategies and senescence-induced therapies to enhance the antitumor effect of hepatocellular senescence in HCC, such as the combination of immune-checkpoint inhibitors and CDK4/6 inhibitors, or senescence-inducing drugs and proapoptotic senolytic reagents. This evidence concerns the gene CDK4 and hepatocellular carcinoma.